Back to Journals » Cancer Management and Research » Volume 12

Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)

Authors Zhu Y, Ye D

Received 31 October 2019

Accepted for publication 18 February 2020

Published 23 March 2020 Volume 2020:12 Pages 2127—2140

DOI https://doi.org/10.2147/CMAR.S236879

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Kenan Onel


Yao Zhu,1,2 Dingwei Ye1,2

On behalf of the Expert Group

1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical School, Fudan University, Shanghai, People’s Republic of China

Correspondence: Dingwei Ye
Department of Oncology, Shanghai Medical School, Fudan University, No. 270 Dongan Road, Shanghai 200032, People’s Republic of China
Tel +86 13 701663571
Email dwyeli@163.com

Abstract: Currently, the basic treatment of advanced prostate cancer is still endocrine therapy, but almost all patients eventually progress to castration-resistant prostate cancer (CRPC). In 2016, the Chinese Expert Consensus on the Diagnosis and Treatment of CRPC which aimed to help Chinese clinicians formulate treatment plans for CRPC was published. In this 2019 update, the 2016 version was updated with the aim of providing a more appropriate reference for clinical practice, standardizing CRPC patient management, and facilitating decision-making. The consensus is evidence-based and reviews the optimal therapeutic recommendations for CRPC management in China by taking into consideration the clinical characteristics of Chinese patients; drug availability, efficacy and safety; and recent advancements and developments in the international medical arena.

Keywords: prostate cancer, castration-resistant, metastases, treatment, expert consensus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]